51 related articles for article (PubMed ID: 20556390)
1. The myeloproliferative neoplasm-associated JAK2 46/1 haplotype is not overrepresented in chronic myelogenous leukemia.
Spolverini A; Jones AV; Hochhaus A; Pieri L; Cross NC; Vannucchi AM
Ann Hematol; 2011 Mar; 90(3):365-6. PubMed ID: 20556390
[No Abstract] [Full Text] [Related]
2. JAK2-V617F and BCR-ABL--double jeopardy?
Krämer A
Leuk Res; 2008 Oct; 32(10):1489-90. PubMed ID: 18439674
[No Abstract] [Full Text] [Related]
3. JAK2 46/1 haplotype predisposes to splanchnic vein thrombosis-associated BCR-ABL negative classic myeloproliferative neoplasms.
Villani L; Bergamaschi G; Primignani M; Rosti V; Carolei A; Poletto V; Catarsi P; Spolverini A; Vannucchi AM; Barosi G
Leuk Res; 2012 Jan; 36(1):e7-9. PubMed ID: 21890200
[No Abstract] [Full Text] [Related]
4. The G allele of the JAK2 rs10974944 SNP, part of JAK2 46/1 haplotype, is strongly associated with JAK2 V617F-positive myeloproliferative neoplasms.
Trifa AP; Cucuianu A; Petrov L; Urian L; Militaru MS; Dima D; Pop IV; Popp RA
Ann Hematol; 2010 Oct; 89(10):979-83. PubMed ID: 20422415
[TBL] [Abstract][Full Text] [Related]
5. BCR-ABL positive chronic myeloid leukemia with concurrent JAK2(V617F) positive myelodysplastic syndrome/myeloproliferative neoplasm (RARS-T).
Gattenlohner S; Völker HU; Etschmann B; Einsele H; Müller-Hermelink HK
Am J Hematol; 2009 May; 84(5):306-7. PubMed ID: 18951468
[No Abstract] [Full Text] [Related]
6. JAK2, 46/1 haplotype and chronic myelogenous leukemia: diagnostic and therapeutic potential.
Campiotti L; Elli L; Suter MB; Guasti L; Pallotti F
Clin Chem Lab Med; 2019 Dec; 58(1):e24-e26. PubMed ID: 31339852
[No Abstract] [Full Text] [Related]
7. Genetic factors in chronic inflammation: single nucleotide polymorphisms in the STAT-JAK pathway, susceptibility to DNA damage and Crohn's disease in a New Zealand population.
Ferguson LR; Han DY; Fraser AG; Huebner C; Lam WJ; Morgan AR; Duan H; Karunasinghe N
Mutat Res; 2010 Aug; 690(1-2):108-15. PubMed ID: 20109474
[TBL] [Abstract][Full Text] [Related]
8. JAK2 mutation and atypical chronic myeloid leukemia.
Campiotti L; Uccella S; Appio L; Pallotti F; La Rosa S; Capella C; Venco A
Leuk Res; 2009 Sep; 33(9):e166-7. PubMed ID: 19427035
[No Abstract] [Full Text] [Related]
9. Analysis of the exon 12 and 14 mutations of the JAK2 gene in Philadelphia chromosome-positive leukemia.
Inami M; Yamaguchi H; Hasegawa S; Mitamura Y; Kosaka F; Kobayashi A; Kimura S; Dan K; Inokuchi K
Leukemia; 2008 Jan; 22(1):216. PubMed ID: 17851549
[No Abstract] [Full Text] [Related]
10. Insights into JAK2-V617F mutation in CML.
Büsche G; Hussein K; Bock O; Kreipe H
Lancet Oncol; 2007 Oct; 8(10):863-4. PubMed ID: 17913656
[No Abstract] [Full Text] [Related]
11. JAK2V617F allele burden, JAK2 46/1 haplotype and clinical features of Chinese with myeloproliferative neoplasms.
Wang J; Xu Z; Liu L; Gale RP; Cross NC; Jones AV; Qin T; Ai X; Xu J; Zhang T; Sun X; Li Q; Zhang P; Zhang Y; Xiao Z
Leukemia; 2013 Aug; 27(8):1763-7. PubMed ID: 23337930
[No Abstract] [Full Text] [Related]
12. A new potential oncogenic mutation in the FERM domain of JAK2 in BCR/ABL1-negative and V617F-negative chronic myeloproliferative neoplasms revealed by a comprehensive screening of 17 tyrosine kinase coding genes.
Aranaz P; Ormazábal C; Hurtado C; Erquiaga I; Calasanz MJ; García-Delgado M; Novo FJ; Vizmanos JL
Cancer Genet Cytogenet; 2010 May; 199(1):1-8. PubMed ID: 20417861
[TBL] [Abstract][Full Text] [Related]
13. Response to imatinib in a patient with chronic myeloid leukemia simultaneously expressing p190(BCR-ABL) oncoprotein and JAK2V617F mutation.
Caocci G; Atzeni S; Orrù N; Littera R; Culurgioni F; Marongiu F; La Nasa G
Leuk Res; 2010 Jan; 34(1):e27-9. PubMed ID: 19748671
[No Abstract] [Full Text] [Related]
14. Development of chronic myeloid leukemia in a patient previously diagnosed with a JAK2-positive myeloproliferative neoplasm.
De Bruyne S; Steel E; Petrick M; Denys B; Vandepoele K; Van Roy N; Degandt S; Ghys T; Louagie H
Clin Chem Lab Med; 2021 Sep; 59(10):e392-e394. PubMed ID: 33964201
[No Abstract] [Full Text] [Related]
15. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
[TBL] [Abstract][Full Text] [Related]
16. JAK2 inhibitors: not the next imatinib but researchers see other possibilities.
Garber K
J Natl Cancer Inst; 2009 Jul; 101(14):980-2. PubMed ID: 19584324
[No Abstract] [Full Text] [Related]
17. Polymorphisms in the Janus kinase 2 (JAK)/signal transducer and activator of transcription (STAT) genes: putative association of the STAT gene region with familial breast cancer.
Vaclavicek A; Bermejo JL; Schmutzler RK; Sutter C; Wappenschmidt B; Meindl A; Kiechle M; Arnold N; Weber BH; Niederacher D; Burwinkel B; Bartram CR; Hemminki K; Försti A
Endocr Relat Cancer; 2007 Jun; 14(2):267-77. PubMed ID: 17639043
[TBL] [Abstract][Full Text] [Related]
18. The Janus Kinase 2 (JAK2) V617F mutation in hematological malignancies in México.
Ruiz-Argüelles GJ; Garcés-Eisele J; Reyes-Núñez V; Ruiz-Delgado GJ; Navarro-Vázquez M; González-Carrillo ML
Rev Invest Clin; 2006; 58(5):458-61. PubMed ID: 17408106
[TBL] [Abstract][Full Text] [Related]
19. Lack of association of XRCC1 codon 399Gln polymorphism with chronic myelogenous leukemia.
Deligezer U; Akisik EE; Dalay N
Anticancer Res; 2007; 27(4B):2453-6. PubMed ID: 17695538
[TBL] [Abstract][Full Text] [Related]
20. [The investigation of JAK2 V617F point mutation in myeloproliferative disorders by allele-specific polymerase chain reaction in combination with sequence analysis].
Zhang SJ; Li WD; Song JH; Xu W; Qiu HX; Li JY
Zhonghua Yi Xue Za Zhi; 2007 Aug; 87(30):2109-12. PubMed ID: 17988529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
